Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 May;71(5):1289–1296. doi: 10.1172/JCI110879

Isolation and chemical characterization of 2-hydroxybenzoylglycine as a drug binding inhibitor in uremia.

D M Lichtenwalner, B Suh, M R Lichtenwalner
PMCID: PMC436990  PMID: 6853715

Abstract

An organic compound that inhibits drug binding in uremia has been isolated from the sera of chronic renal failure patients, and its chemical structure has been determined. Addition of the compound to normal human sera in vitro resulted in drug binding defects similar to those seen in uremia. The purification of this substance was accomplished by n-butyl chloride extraction of acidified (pH 3.0) uremic sera followed by column chromatography, thin-layer chromatography, and paper electrophoresis. From analytical studies including ultraviolet and fluorescence spectroscopy, gas chromatography, chemical ionization and electron impact mass spectrometry, and proton nuclear magnetic resonance spectroscopy, the chemical structure of the uremic binding inhibitor was deduced to be 2-hydroxybenzoylglycine. This confirms the hypothesis that the drug binding defect in uremia is due to the accumulation of endogenous metabolic products rather than an intrinsic structural defect in albumin.

Full text

PDF
1289

Images in this article

1291Image
on p.1291

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARMSTRONG M. D., SHAW K. N., WALL P. E. The phenolic acids of human urine; paper chromatography of phenolic acids. J Biol Chem. 1956 Jan;218(1):293–303. [PubMed] [Google Scholar]
  2. Austad W. I., Clamp J. R., Westall R. G. Salicyluric acid as a metabolite of L-tryptophan. Nature. 1965 Aug 14;207(998):757–757. doi: 10.1038/207757a0. [DOI] [PubMed] [Google Scholar]
  3. BOOTH A. N., ROBBINS D. J., DUNKLEY W. L. Occurrence of salicyluric acid in milk. Nature. 1962 Apr 21;194:290–291. doi: 10.1038/194290a0. [DOI] [PubMed] [Google Scholar]
  4. Boobis S. W. Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther. 1977 Aug;22(2):147–153. doi: 10.1002/cpt1977222147. [DOI] [PubMed] [Google Scholar]
  5. Craig W. A., Evenson M. A., Sarver K. P., Wagnild J. P. Correction of protein binding defect in uremic sera by charcoal treatment. J Lab Clin Med. 1976 Apr;87(4):637–647. [PubMed] [Google Scholar]
  6. Feingold B. F. Recognition of food additives as a cause of symptoms of allergy. Ann Allergy. 1968 Jun;26(6):309–313. [PubMed] [Google Scholar]
  7. HICKS J. M., YOUNG D. S., WOOTTON I. D. THE EFFECT OF URAEMIC BLOOD CONSTITUENTS ON CERTAIN CEREBRAL ENZYMES. Clin Chim Acta. 1964 Mar;9:228–235. doi: 10.1016/0009-8981(64)90099-3. [DOI] [PubMed] [Google Scholar]
  8. Kober A., Sjöholm I., Borgå O., Odar-Cederlöf I. Protein binding of diazepam and digitoxin in uremic and normal serum. Biochem Pharmacol. 1979 Apr 1;28(7):1037–1042. doi: 10.1016/0006-2952(79)90300-9. [DOI] [PubMed] [Google Scholar]
  9. Kopple J. D., Fukuda S. Effects of amino acid infusion and renal failure on the uptake and release of amino acids by the dog kidney. Am J Clin Nutr. 1980 Jul;33(7):1363–1372. doi: 10.1093/ajcn/33.7.1363. [DOI] [PubMed] [Google Scholar]
  10. Lichtenwalner D. M., Suh B., Lorber B., Rudnick M. R., Craig W. A. Correction of drug binding defects in uremia in vitro by anion exchange resin treatment. Biochem Pharmacol. 1982 Nov 1;31(21):3483–3487. doi: 10.1016/0006-2952(82)90630-x. [DOI] [PubMed] [Google Scholar]
  11. Lichtenwalner D. M., Suh B., Lorber B., Rudnick M. R., Craig W. A. Partial purification and characterization of the drug-binding-defect inducer in uremia. J Lab Clin Med. 1981 Jan;97(1):72–81. [PubMed] [Google Scholar]
  12. Reidenberg M. M., Affrime M. Influence of disease on binding of drugs to plasma proteins. Ann N Y Acad Sci. 1973 Nov 26;226:115–126. doi: 10.1111/j.1749-6632.1973.tb20474.x. [DOI] [PubMed] [Google Scholar]
  13. Reidenberg M. M., Odar-Cederlöf I., von Bahr C., Borgå O., Sjöqvist F. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971 Jul 29;285(5):264–267. doi: 10.1056/NEJM197107292850506. [DOI] [PubMed] [Google Scholar]
  14. Saito A., Niwa T., Maeda K., Kobayashi K., Yamamoto Y., Ohta K. Tryptophan and indolic tryptophan metabolites in chronic renal failure. Am J Clin Nutr. 1980 Jul;33(7):1402–1406. doi: 10.1093/ajcn/33.7.1402. [DOI] [PubMed] [Google Scholar]
  15. Shoeman D. W., Azarnoff D. L. The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology. 1972;7(3):169–177. doi: 10.1159/000136286. [DOI] [PubMed] [Google Scholar]
  16. Sjöholm I., Kober A., Odar-Cederlöf I., Borgåa O. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol. 1976 May 15;25(10):1205–1213. doi: 10.1016/0006-2952(76)90370-1. [DOI] [PubMed] [Google Scholar]
  17. Speer F. Allergy to methyl salicylate. Ann Allergy. 1979 Jul;43(1):36–37. [PubMed] [Google Scholar]
  18. de Torrente A., Glazer G. B., Gulyassy P. Reduced in vitro binding of tryptophan by plasma in uremia. Kidney Int. 1974 Oct;6(4):222–229. doi: 10.1038/ki.1974.103. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES